Mike: Assume the reference is to today's news. Here's a clip...
At least one company can go up these days !.
Xenova Group plc Preliminary Results for the Year to December 31st
1996 Announcement of Collaboration Agreement with Zeneca Highlights
- Anti-cancer therapies XR5000 and XR9051 enter Phase II and Phase I
clinical trials respectively - New US-based subsidiary, MetaXen,
founded to provide state-of-the-art computational drug design and
combinatorial chemistry - Development of QTC drug discovery system
to accelerate drug lead identification, with investment by
Warner-Lambert secured - Drug discovery collaboration agreement
announced in January with Bristol Myers Squibb
SLOUGH, U.K., March 19 /PRNewswire/ -- The following release was
issued today by Xenova Group plc:
Xenova also announces today that it has reached agreement with
Zeneca to collaborate in the discovery of novel pharmaceuticals from
Xenova's natural compound libraries (QTC). The agreement provides
for payment for the provision of the libraries and Xenova will be
eligible for milestone payments and royalties on drugs developed by
Zeneca from them.
Commenting on the results and on the collaboration with Zeneca,
Dr. Louis Nisbet, Chief Executive of Xenova Group, said:
"There has been enormous progress at Xenova during the past
year, as further demonstrated today by the announcement of our
collaboration with another of the world's leading pharmaceutical companies, Zeneca."
Xenova is an emerging biopharmaceutical group based in the UK
and the US, which is developing its own drugs, focused on cancer and
thrombosis, as well as exploiting its leading position in natural
products technology to discover drugs for both itself and 8 current
partners. The Company successfully completed the listing of its
shares on the London Stock Exchange in December 1996, raising 22.6
million pounds sterling before expenses.
..... SEE PRNewswire FOR REMAINDER
Mike, I could not access the web site without your password :-)
Dave. |
